» Articles » PMID: 35053298

NLRP6 Inflammasome Modulates Disease Progression in a Chronic-Plus-Binge Mouse Model of Alcoholic Liver Disease

Overview
Journal Cells
Publisher MDPI
Date 2022 Jan 21
PMID 35053298
Authors
Affiliations
Soon will be listed here.
Abstract

A considerable percentage of the population is affected by alcoholic liver disease (ALD). It is characterized by inflammatory signals from the liver and other organs, such as the intestine. The NLR family pyrin domain containing 6 (NLRP6) inflammasome complex is one of the most important inflammatory mediators. The aim of this study was to evaluate a novel mouse model for ALD characterized by 8-week chronic-plus-binge ethanol administration and to investigate the role of NLRP6 inflammasome for intestinal homeostasis and ALD progression using mice. We showed that chronic-plus-binge ethanol administration triggers hepatic steatosis, injury, and neutrophil infiltration. Furthermore, we discovered significant changes of intestinal microbial communities, including increased relative abundances of bacteria within the phyla and , as well as reduced . In this ALD model, inhibiting NLRP6 signaling had no effect on liver steatosis or damage, but had a minor impact on intestinal homeostasis via affecting intestinal epithelium function and gut microbiota. Surprisingly, loss resulted in significantly decreased hepatic immune cell infiltration. As a result, our novel mouse model encompasses several aspects of human ALD, such as intestinal dysbiosis. Interfering with NLRP6 inflammasome activity reduced hepatic immune cell recruitment, indicating a disease-aggravating role of NLRP6 during ALD.

Citing Articles

Pharmacotherapy of Liver Fibrosis and Hepatitis: Recent Advances.

Zhao L, Tang H, Cheng Z Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770566 PMC: 11677259. DOI: 10.3390/ph17121724.


Ethanol modulates astrocyte activation and neuroinflammation via miR-339/NLRP6 inflammasome signaling.

Singh S, Kannan M, Oladapo A, Deshetty U, Ray S, Buch S Free Radic Biol Med. 2024; 226:1-12.

PMID: 39522566 PMC: 11688707. DOI: 10.1016/j.freeradbiomed.2024.11.014.


Metagenomic comparison of intestinal microbiota between normal and liver fibrotic rhesus macaques (Macaca mulatta).

Wei Y, Li J, Zhu B, Hu Q, Lan M, Zhou J Sci Rep. 2024; 14(1):15677.

PMID: 38977718 PMC: 11231266. DOI: 10.1038/s41598-024-64397-7.


Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation.

Taru V, Szabo G, Mehal W, Reiberger T J Hepatol. 2024; 81(5):895-910.

PMID: 38908436 PMC: 11881887. DOI: 10.1016/j.jhep.2024.06.016.


Endogenous ethanol production in health and disease.

Meijnikman A, Nieuwdorp M, Schnabl B Nat Rev Gastroenterol Hepatol. 2024; 21(8):556-571.

PMID: 38831008 DOI: 10.1038/s41575-024-00937-w.


References
1.
McClain C, Cohen D, Dinarello C, Cannon J, Shedlofsky S, Kaplan A . Serum interleukin-1 (IL-1) activity in alcoholic hepatitis. Life Sci. 1986; 39(16):1479-85. DOI: 10.1016/0024-3205(86)90554-0. View

2.
Levy M, Thaiss C, Zeevi D, Dohnalova L, Zilberman-Schapira G, Mahdi J . Microbiota-Modulated Metabolites Shape the Intestinal Microenvironment by Regulating NLRP6 Inflammasome Signaling. Cell. 2015; 163(6):1428-43. PMC: 5665753. DOI: 10.1016/j.cell.2015.10.048. View

3.
Edgar R . UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nat Methods. 2013; 10(10):996-8. DOI: 10.1038/nmeth.2604. View

4.
Fukui H . Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?. Diseases. 2019; 7(4). PMC: 6956030. DOI: 10.3390/diseases7040058. View

5.
Galvez E, Iljazovic A, Gronow A, Flavell R, Strowig T . Shaping of Intestinal Microbiota in Nlrp6- and Rag2-Deficient Mice Depends on Community Structure. Cell Rep. 2017; 21(13):3914-3926. DOI: 10.1016/j.celrep.2017.12.027. View